Hepatocellular carcinoma (HCC) has constituted a significant health burden worldwide, and
patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies
worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited …

Hepatocellular carcinoma (HCC) is a highly lethal disease that is resistant to conventional
cytotoxic drugs. Historically, effective systemic treatment options have not been available for …

Hepatocellular carcinoma (HCC) is prevalent worldwide with suboptimal therapeutic
outcomes. The advancement of therapeutic options and the development of new systemic …

Hepatocellular carcinoma (HCC) accounts for 6% of all cancers worldwide. In the United
States, the incidence is expected to increase due to the increased rate of hepatitis C viral …

Simple Summary Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of
the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of …

Simple Summary Hepatocellular carcinoma is the fourth leading cause of cancer-related
mortality worldwide and a major health problem. Overall survival is poor, with a five-year …

Hepatocellular carcinoma (HCC) is one of the most common and deadliest cancers
worldwide with a rising incidence in the Western world. HCCs are characterized by high …

The evolving treatment paradigm of advanced hepatocellular c... : Current Opinion in
Oncology The evolving treatment paradigm of advanced hepatocellular carcinoma: putting …

Introduction: While sorafenib dominated the therapeutic arena in advanced hepatocellular
carcinoma (HCC) for almost a decade, newer agents and combinations have been changing …